Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: Outcomes from the 4-Week Maximal Usage Trial

Main Article Content

Amy Paller
Adelaide A. Hebert
Philip M. Brown
Victoria Butners
Nancy Fitzgerald
Mercedes E. Gonzalez
Stephen C. Piscitelli


atopic dermatitis, eczema, maximal usage pharmacokinetics, tapinarof cream 1% once daily, AhR agonist


1. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf.Accessed August 2023.

2. Peppers J, et al. J Am Acad Dermatol. 2019;80:89–98.

3. Paller A, et al. J Am Acad Dermatol. 2021;84:632–638.

4. Lebwohl M, et al. N Engl J Med. 2021;385:2219–2229. 5. Strober B, et al. J Am Acad Dermatol. 2022;87:800–806.

6. Bissonnette R, et al. Clin Pharmacol Drug Dev. 2018;7:524–531.

7. Jett JE, et al. Am J Clin Dermatol. 2022;23:83–91.

8. Hanifin JM and Rajka G. Acta Dermato-Venereologica. 1980;60: Suppl 92, 44–47.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>